Metvixia

Generic name: Methyl Aminolevulinate (topical)
Drug class: Topical photochemotherapeutics

Usage of Metvixia

Metvixia cream makes your skin more sensitive to light. It works by causing a reaction with light that can destroy certain types of diseased skin cells.

Metvixia cream is used in combination with red light therapy to treat to treat skin growths on the face and scalp called actinic keratosis of the face and scalp.

Metvixia cream is only used for actinic keratosis skin growths that are thin and not dark colored. Actinic keratosis skin growths are not cancer and are caused partly by too much sun exposure.

Metvixia side effects

Get emergency medical help if you have any of these signs of an allergic reaction to Metvixia: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

severe stinging, burning, redness, oozing, or swelling of treated skin areas (especially if these effects get worse or last longer than 3 weeks).

Common Metvixia side effects may include:

skin redness, warmth, burning, stinging, or swelling;

blisters, skin ulcers; or

peeling or crusting of treated skin.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Metvixia

You should not use Metvixia cream if you are allergic to methyl aminolevulinate, or if you have:

an allergy to peanuts or almonds;

an allergy to porphyrins; or

if your skin is especially sensitive to light.

To make sure Metvixia is safe for you, tell your doctor if you have:

a bleeding disorder; or

a history of skin cancer or skin growths.

FDA pregnancy category C. It is not known whether Metvixia will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medicine.

It is not known whether methyl aminolevulinate passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

Relate drugs

How to use Metvixia

Usual Adult Dose for Keratosis:

Non-hyperkeratotic, nonpigmented actinic keratoses of the face and scalp in immunocompetent patients: Apply directly on lesion(s), up to a total of 1 gram (half tube) per each treatment session. Two sessions one week apart should be administered. Cream application should be followed by photoactivation with Aktilite CL 128 lamp red light illumination. Prior to application of Metvixia cream, a small dermal curette should be used to remove scales and crusts and to roughen the surface of the lesion(s). An approximately 1 mm-thick layer of cream should be applied with a spatula to each lesion and the surrounding 5 mm of normal skin. The application area should then be covered with an occlusive, nonabsorbent dressing for 3 hours (2.5 to 4 hours). Multiple lesions may be treated during the same session, up to an area of 80 X 180 mm (the area of illumination). Following removal of the occlusive dressing, clean the area with saline and gauze before beginning Aktilite red light treatment. The light dose to be used is 37 J/cm2, and the lamp should be placed 50 to 80 mm (2 to 3.2 inches) from the skin. The required illumination time (7 to 10 minutes) is calculated automatically. Both the patient and operator should wear appropriate eye protection during illumination and avoid staring into the beam. The illumination stops automatically. If Aktilite red light treatment is interrupted or stopped for any reason, it may be restarted. If the patient cannot have the red light treatment during the prescribed period after application, the cream should be rinsed off and the patient should protect the exposed area from sunlight and prolonged or intense light for at least 48 hours.

Warnings

You should not use Metvixia if you are allergic to porphyrins, peanuts or almonds, or if your skin is especially sensitive to light.

Before you are treated with Metvixia, tell your doctor about all of your medical conditions. Also tell your doctor about all other medications you use, especially drugs that can make your skin more sensitive to sunlight, such as certain antibiotics, heart or blood pressure medications, diuretics (water pills), sulfa drugs, oral diabetes medications, or NSAID pain or arthritis medicines.

Metvixia is applied by a healthcare provider in a clinic setting. For at least 48 hours after your treatment, avoid exposing treated skin to sunlight, sunlamps, tanning beds, or other bright lights. Sunscreen is not effective enough to protect treated skin from harm caused by bring light during this time. Wear protective clothing whenever you are outdoors. Call your doctor at once if you have severe stinging, burning, redness, oozing, or swelling of treated skin areas, especially if you have these effects for longer than 3 weeks after treatment.

It may take several weeks before you notice improvement in your skin condition. Your doctor will need to check your treated skin 3 months after the end of your last treatment with Metvixia.

Your skin lesions may need to be treated more than once, and they may come back after treatment. Talk to your doctor about the number of treatments needed to treat your condition.

What other drugs will affect Metvixia

It is not likely that other drugs you take orally or inject will have an effect on topically applied Metvixia. But many drugs can interact with each other. Tell each of your health care providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.